Inhaled Treprostinil for PAH: Open-label Extension
NCT01557660 · Status: WITHDRAWN · Phase: PHASE3 · Type: INTERVENTIONAL
Last updated 2012-03-26
Summary
Open-label extension of RIN-PH-302.
Conditions
Interventions
- DRUG
-
inhaled treprostinil
0.6mg/mL inhalation solution, up to 12 breaths four times a day
Sponsors & Collaborators
-
United Therapeutics
lead INDUSTRY
Study Design
- Allocation
- NA
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2012-06-30
- Primary Completion
- 2018-12-31
- Completion
- 2018-12-31
More Related Trials
-
An Open-Label Extension Trial of UT-15C Sustained-release (SR) in Subjects With Pulmonary Arterial Hypertension
NCT01027949 ·Status: COMPLETED ·Phase: PHASE3
-
An Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) for Pulmonary Arterial Hypertension (PAH)
NCT05649748 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2/PHASE3
-
Phase III Clinical Worsening Study of UT-15C in Subjects With PAH Receiving Background Oral Monotherapy
NCT01560624 ·Status: COMPLETED ·Phase: PHASE3
-
Safety, Efficacy and Treatment Satisfaction in Patients With PAH Rapidly Switched From Epoprostenol to Remodulin
NCT00373360 ·Status: COMPLETED ·Phase: PHASE4
-
Oral Treprostinil in Subjects With Pulmonary Hypertension Associated With Heart Failure With Preserved Ejection Fraction
NCT03037580 ·Status: TERMINATED ·Phase: PHASE3
-
Efficacy and Safety of Treprostinil in Intermediate-Risk Pulmonary Arterial Hypertension
NCT07177703 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
Safety and Tolerability of Inhaled Treprostinil in Adult PH Due to COPD
NCT03012646 ·Status: WITHDRAWN ·Phase: PHASE2
-
An Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) for Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)
NCT05649722 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
FREEDOM DR: Oral Treprostinil in Combination With an Endothelin Receptor Antagonist (ERA) and/or a Phosphodiesterase-5 (PDE-5) Inhibitor or as Monotherapy for the Treatment of Pulmonary Arterial Hypertension (PAH)
NCT00760916 ·Status: WITHDRAWN ·Phase: PHASE3
-
Oral Treprostinil in Subjects With Pulmonary Hypertension Associated With Pulmonary Fibrosis
NCT02603068 ·Status: WITHDRAWN ·Phase: PHASE2
-
Safety Evaluation of Inhaled Treprostinil Administration Following Transition From Inhaled Ventavis in Pulmonary Arterial Hypertension (PAH) Subjects
NCT00741819 ·Status: COMPLETED ·Phase: PHASE4
-
A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Treprostinil Palmitil Inhalation Powder in Participants With Pulmonary Arterial Hypertension
NCT05147805 ·Status: COMPLETED ·Phase: PHASE2
-
Remodulin® to Oral Treprostinil Transition
NCT01588405 ·Status: COMPLETED ·Phase: PHASE2
-
An Open-Label Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)
NCT07234032 ·Status: NOT_YET_RECRUITING ·Phase: PHASE3
-
A Study of Treprostinil Palmitil Inhalation Powder (TPIP) In Pulmonary Arterial Hypertension (PAH)
NCT04791514 ·Status: TERMINATED ·Phase: PHASE2
-
Safety, Tolerability, and Pharmacokinetics of Oral Treprostinil in Pediatric PAH Patients Aged 7 to 17 Years
NCT02276872 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of Treprostinil to Treat Interstitial Lung Disease Pulmonary Hypertension
NCT05564637 ·Status: COMPLETED ·Phase: PHASE2
-
Open-label Extension of Oral Treprostinil in Subjects With PH Associated With HFpEF
NCT03043651 ·Status: TERMINATED ·Phase: PHASE3
-
Study Of Right Ventricular Performance In PAH Patients Treated With Rapid Dose Treprostinil (Remodulin)
NCT02074449 ·Status: COMPLETED
-
An Expanded Access Study to Assess Treprostinil Palmitil Inhalation Powder (TPIP) for Participants With Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)
NCT06939647 ·Status: AVAILABLE
-
FREEDOM - M: Oral Treprostinil as Monotherapy for the Treatment of Pulmonary Arterial Hypertension (PAH)
NCT00325403 ·Status: COMPLETED ·Phase: PHASE3
-
Subcutaneous Treprostinil as a Bridge to Lung Transplantation in Severe Pulmonary Hypertension: A Single-Arm Retrospective Study
NCT06605326 ·Status: COMPLETED ·Phase: PHASE4
-
A Real-World Registry Investigating TReprostInil sodiUM in Pulmonary Hypertension (Re-TRIUMPH)
NCT05553015 ·Status: RECRUITING
-
A Study to Observe the Safety, Tolerability, and Efficacy of Remodulin
NCT06603285 ·Status: NOT_YET_RECRUITING
-
A Phase 3 Adaptive Study to Evaluate the Safety and Efficacy of Inhaled Treprostinil in Participants With Pulmonary Hypertension (PH) Due to Chronic Obstructive Pulmonary Disease (COPD)
NCT03496623 ·Status: TERMINATED ·Phase: PHASE3